Molecular Targeted Radiosensitizers Opportunities and Challenges
Molecular Targeted Radiosensitizers: Opportunities and Challenges provides the reader with a comprehensive review of key pre-clinical research components required to identify effective radiosensitizing drugs. The book features discussions on the mechanism
- PDF / 8,581,571 Bytes
- 370 Pages / 439.43 x 683.15 pts Page_size
- 80 Downloads / 139 Views
Henning Willers Iris Eke Editors
Molecular Targeted Radiosensitizers Opportunities and Challenges
Cancer Drug Discovery and Development
Series Editor Beverly A. Teicher Bethesda, MD, USA
The Cancer Drug Discovery and Development series (Beverly A Teicher, series editor) is the definitive book series in cancer research and oncology, providing comprehensive coverage of specific topics and the field. Volumes cover the process of drug discovery, preclinical models in cancer research, specific drug target groups and experimental and approved therapeutic agents. The volumes are current and timely, anticipating areas where experimental agents are reaching FDA approval. Each volume is edited by an expert in the field covered and chapters are authored by renowned scientists and physicians in their fields of interest. More information about this series at http://www.springer.com/series/7625
Henning Willers • Iris Eke Editors
Molecular Targeted Radiosensitizers Opportunities and Challenges
Editors Henning Willers Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston, MA, USA
Iris Eke Department of Radiation Oncology Stanford University School of Medicine Stanford, CA, USA
ISSN 2196-9906 ISSN 2196-9914 (electronic) Cancer Drug Discovery and Development ISBN 978-3-030-49700-2 ISBN 978-3-030-49701-9 (eBook) https://doi.org/10.1007/978-3-030-49701-9 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Humana imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
It has been almost an entire century since Dr. Hermann Holthusen of Hamburg, Germany, correctly surmised that the relationship between the probability of tumor control and the total dose of radiation deliver
Data Loading...
